Loading asset research
Nektar Therapeutics Common Stock
NKTRNasdaq · USD · StocksQuote as of · Exchange session not verified$69.77
-1.25%
Today
NKTR
Loading 1D prices…
Market cap
$2.4B
Volume
784.1K
52w high
$109.0052w low
$33.40Company profile
Nektar Therapeutics Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Francisco, CA, United States
Employees
63
Fiscal year end
1231
CIK
906709
Session & valuation
Open$71.41
Previous close$70.65
Day high$71.41
Day low$68.35
30-day avg. volume599.4K
Outstanding shares34.1M
Diluted EPS-$9.73
Latest annual period
P/E (trailing)-7.17
P/E (forward)-6.43
Price / book2.64
Beta1.15
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BRVEBraveheart Bio Inc. Common Stock | $2.4B | $0.00 | — | -$5.32 | -2.02% | Buy |
| VRDNViridian Therapeutics Inc. Common Stock | $2.4B | $70.8M | -483.56% | -$3.32 | -4.76% | Buy |
| HRMYHarmony Biosciences Holdings Inc. Common Stock | $2.4B | $868.5M | +18.27% | $2.71 | +1.02% | Hold |
| MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock | $2.4B | $185.7M | -70.42% | -$0.90 | -3.12% | Buy |
| SUPNSupernus Pharmaceuticals Inc. Common Stock | $2.4B | $719M | -5.37% | -$0.68 | -0.10% | Buy |